CellCentric’s leadership and advisory team has deep experience of drug discovery, development and commercialisation in oncology.
Chairman & CEO, Board Member
Research & Operations Director, Board Member
Finance Director & Company Secretary
Chief Medical Officer
Clinical Operations Director
Senior Clinical Trials Manager
Clinical Trials Manager
Investor Director, Board Member
Director, NCI-designated Sidney Kimmel Cancer Center; Chair, Dept. of Cancer Biology at Thomas Jefferson University
Regius Professor of Cancer Research, Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal Marsden Hospital
Chief Development Advisor. Prof Experimental Cancer Medicine, Uni. Manchester. Former Head Global Early Clinical Development, AstraZeneca
Senior Oncology Consultant; Former Head, Global Oncology Research, Johnson & Johnson
Clinical Operations Consultant (Europe). Previously Theragnostics, AstraZeneca
Toxicology Consultant. ApconiX. Previously UK Discovery Safety Director, AstraZeneca
CMC Consultant. Managing Director, Synth-Isis. Previously with OSI, Abbott
Formulation, SEDA Pharmaceutical Development Services Ltd. Formerly AstraZeneca
Clinical Research Associate. Previously Addenbrooke’s Hospital, Napp Pharmaceuticals
Clinical Research Associate. Previously Replimmune, AstraZeneca, NHS.
Clinical Research Associate. Previously Iqvia, Roche, Lilly, Novartis.
Clinical Research Associate. Previously Replimmune, AZ, Parexel, Iqvia.
Clinical Research Associate. Previously Drug Discovery Unit CRUK Manchester, The Christie Hospital.
Clinical Pharmacology and DMPK. Formerly GSK, AstraZeneca
Statistical Consultant. Alpha Medical Statistics, formerly AstraZeneca.
GCP Quality Assurance. Richmond QA Consultancy. Previously Roche, Pfizer, Dainippon Sumitomo Pharma.
QA/QC Consultant. Director/Owner, Cogent QA Ltd, formerly British Biotech, Abbott
Consultant Scientist (mutation analysis), Oncognition. Previously AstraZeneca
We are driven to develop and prove a first-in-class cancer drug that delivers clear clinical benefit to patients that have limited other options.
Our drug discovery and development builds upon our deep foundation in epigenetics, and collaboration with multiple world leading researchers in the space.
Applications of CCS1477